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Active neurons exert a mitogenic effect on normal
neural precursor and oligodendroglial precursor
cells, the putative cellular origins of high-grade gli-
oma (HGG). By using optogenetic control of cortical
neuronal activity in a patient-derived pediatric glio-
blastoma xenograft model, we demonstrate that
active neurons similarly promote HGG proliferation
and growth in vivo. Conditioned medium from opto-
genetically stimulated cortical slices promoted
proliferation of pediatric and adult patient-derived
HGG cultures, indicating secretion of activity-regu-
lated mitogen(s). The synaptic protein neuroligin-3
(NLGN3) was identified as the leading candidate
mitogen, and soluble NLGN3 was sufficient and
necessary to promote robust HGG cell proliferation.
NLGN3 induced PI3K-mTOR pathway activity and
feedforward expression of NLGN3 in glioma cells.
NLGN3 expression levels in human HGG negatively
correlated with patient overall survival. These find-
ings indicate the important role of active neurons in
the brain tumor microenvironment and identify
secreted NLGN3 as an unexpected mechanism pro-
moting neuronal activity-regulated cancer growth.INTRODUCTION
High-grade gliomas (HGG), the leading cause of brain tumor
death in both children and adults, occur in a striking spatiotem-
poral pattern highlighting the critical importance of the tumor
microenvironment. Molecularly defined subtypes of HGG parse
by neuroanatomical site of origin and patient age, with pontineand thalamic HGGs typically occurring inmid-childhood, cortical
gliomas of childhood occurring in older children and young
adults, and HGG of later adulthood occurring chiefly in the fron-
totemporal lobes (Khuong-Quang et al., 2012; Schwartzentruber
et al., 2012; Sturm et al., 2012; Wu et al., 2012). These age and
neuroanatomical predilections of gliomagenesis point to interac-
tions between cell of origin and microenvironment, suggesting
dysregulation of neurodevelopment and/or plasticity.
Microenvironmental determinants of glioma cell behavior are
incompletely understood, although important relationships be-
tween glioma cells and neighboring microglia, astrocytes, and
vascular cells have recently come to light (Charles et al., 2011;
Pyonteck et al., 2013; Silver et al., 2013). While cellular origins
of HGG remain unclear, converging evidence implicates oligo-
dendroglial precursor cells (OPCs) and earlier neural precursor
cells (NPCs) as putative cells of origin for many forms of HGG
(Galvao et al., 2014; Liu et al., 2011; Monje et al., 2011; Wang
et al., 2009). Clues to microenvironmental influences driving
HGG growth may thus be inferred from mechanisms governing
the proliferation of normal NPCs andOPCs in the postnatal brain.
We recently demonstrated that neuronal activity exerts a strong
mitogenic effect on normal NPCs and OPCs in juvenile and adult
mammalian brains (Gibson et al., 2014), raising the possibility
that neuronal activity could promote proliferation in HGG.
RESULTS
Optogenetic Control of Cortical Neuronal Activity in a
Patient-Derived Pediatric Cortical HGG Orthotopic
Xenograft Model
To test the role of neuronal activity in HGG growth, we employed
in vivo optogenetic stimulation of premotor cortex in freely
behaving mice bearing patient-derived orthotopic xenografts
of pediatric cortical glioblastoma (GBM; Figure 1A–1C). The
well-characterized Thy1::ChR2 mouse model expressing the
excitatory opsin channelrhodopsin-2 (ChR2) in deep corticalCell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc. 803
Figure 1. Neuronal Activity Promotes High-Grade Glioma Proliferation and Growth In Vivo
(A) In vivo optogenetic high-grade glioma (HGG) orthotopic xenograft model.
(B) Schematic illustration of the optogenetically stimulatable premotor circuit. Thy1::ChR2+ premotor cortex (M2) neurons depicted in blue; primary motor cortex
(M1) projection neurons, green; tumor cells depicted as red dots. Gray shading indicates region of analysis.
(C) Confocal micrograph of infiltrating pHGG (SU-pcGBM2) cells expressing human nuclear antigen (HNA, red), proliferation marker Ki67 (green) in premotor
cortical deep layers and subjacent corpus callosum (MBP, white).
(D and E) Single optogenetic stimulation session paradigm. (D) Proliferation index of pHGG cells in identically manipulated WT;NSG (n = 3) and Thy1::ChR2;NSG
(n = 7) mice, measured by the proportion of HNA+ cells expressing EdU (left graph) or Ki67 (right graph) 24 hr after one optogenetic stimulation session. (E)
Confocal micrograph illustrating proliferating (Ki67+, green) pHGG cells (HNA+, red) xenografted inWT;NSG (‘‘WT’’; left) or Thy1::ChR2;NSGmice (‘‘ChR2’’; right).
(F–H) Repetitive optogenetic stimulation sessions paradigm. Xenografted WT;NSG (n = 5) and Thy1::ChR2;NSG (n = 4) mice evaluated 48 hr after seven daily
sessions of optogenetic stimulation. (F) Proliferation index (Ki67+/HNA+) as in (D) above after seven stimulations. (G) Tumor cell burden increases following 1week
of brief daily optogenetic stimulation sessions, measured as HNA+ cell density within the region of corpus callosum containing active premotor projections; data
normalized to WT mean. (H) Confocal micrographs with differential interference contrast (DIC) background to illustrate regional tissue architecture; HNA+ pHGG
cells (red) are infiltrating premotor cortex and subjacent corpus callosum. Dotted line indicates region of analysis in corpus callosum.
Data shown as mean ± SEM. *p < 0.05, **p < 0.01 by unpaired two-tailed Student’s t test. Scale bars, 100 mm. See also Figure S1 and Movie S1.projection neurons (Arenkiel et al., 2007; Wang et al., 2007) was
crossed onto an immunodeficient background (NOD-SCID-
IL2R g-chain-deficient, NSG), resulting in a mouse model
(Thy1::ChR2;NSG) amenable to both in vivo optogenetics and
orthotopic xenografting. ChR2-expressing neurons respond
with action potentials to 473 nm light pulseswithmillisecond pre-
cision (Arenkiel et al., 2007; Boyden et al., 2005; Wang et al.,
2007). Expression of ChR2 does not alter membrane properties
in the absence of light or neuronal health in the absence or pres-
ence of light under established experimental conditions (Boyden
et al., 2005). When an optical fiber is placed just below the pial
surface (Figure 1B), 10% of the irradiance penetrates midway804 Cell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc.through cortex, thus stimulating the apical dendrites of deep
cortical projection neurons expressing ChR2 (Yizhar et al.,
2011). Stimulating the premotor circuit unilaterally at 20 Hz,
consistent with the 10–40 Hz physiological firing rate of motor
cortex projection neurons, elicits complex motor behavior (unidi-
rectional ambulation; Arenkiel et al., 2007; Gibson et al., 2014;
Wang et al., 2007). Optogenetic stimulation of the premotor cir-
cuit elicits a substantial increase in NPC and OPC proliferation
(Gibson et al., 2014). At baseline, precursor cell proliferation is
equivalent in mice expressing or lacking ChR2 (Gibson et al.,
2014). In this experimental paradigm, themicroglial inflammatory
response to superficial fiber placement and subsequent light
stimulation is minimal in deep cortex, where ChR2-expressing
neurons reside, resolves within days, and is equal in Thy1::ChR2
mice and identically manipulated wild-type (WT) controls
(Gibson et al., 2014).
To develop an orthotopic xenograft model appropriate to the
juvenile premotor cortex, a culture was established from pre-
treatment biopsy tissue of a frontal cortex GBM (WHO grade
IV) from a 15-year-old male (culture designated SU-pcGBM2;
clinical characteristics, genomic characterization and DNA
fingerprinting described in Table S1). These pediatric cortical
HGG (pHGG) cells were xenografted unilaterally into premotor
(M2) cortex of juvenile Thy1::ChR2;NSG mice, resulting in
diffusely infiltrating glioma cells throughout premotor cortex
and subjacent corpus callosum (Figure 1C). WT (no opsin) litter-
mate control NSG mice (WT;NSG) were identically manipulated
for comparison. After tumors were allowed to engraft for
2 months, an optical-neural interface was placed ipsilateral to
the xenograft. The unilateral premotor cortex was optogeneti-
cally stimulated (473 nm, 20 Hz; cycles of 30 s on/90 s off over
30 min) in awake mice, resulting in unidirectional ambulation.
pHGG xenografts did not impede the behavioral response to
evoked premotor circuit activity (Movie S1). Light stimulation
had no behavioral effect in identically manipulated xenografted
WT;NSG mice. Mice were given one dose of EdU to label
proliferating cells at the time of optogenetic manipulation and
were sacrificed 24 hr later to examine acute effects of neural
activity.
Neuronal Activity Promotes High-Grade Glioma Growth
In Vivo
Tumor cell burden and distribution did not differ between groups
at the time of stimulation (p = 0.74; Figures S1A and S1B). Xen-
ografted human tumor cells (human nuclear antigen, HNA+) co-
expressing EdU indicate glioma cells proliferating at the time of
EdU administration and optogenetic stimulation, while co-
expression of Ki67 indicates cells proliferating at the time of sac-
rifice 24 hr later. Within the premotor circuit (Figures 1B and
S1C), the proliferation index of human tumor cells was increased
in optogenetically stimulated Thy1::ChR2;NSG mice compared
to that of identically manipulated WT mice, measured both as
the percent of tumor cells co-expressing EdU (9.83% ± 0.38%
versus 7.43% ± 0.86%; n = 7 Thy1::ChR2;NSG mice, n = 3
WT;NSG mice, respectively; p < 0.05; Figures 1D and 1E) or
co-expressing Ki67 (10.53% ± 0.37% versus 7.48% ± 0.48%;
n = 7 Thy1::ChR2;NSG mice, n = 3 WT;NSG mice, respectively;
p < 0.01, Figures 1D and 1E). This range of observed proliferation
indices is consistent with that of human glioma. Proliferation in-
dex is typically <5% for low-grade astrocytomas, 5%–15% for
anaplastic astrocytomas (WHO grade III), and 10%–20% for
GBMs (WHO grade IV); proliferation indices correlate inversely
with prognosis, with those above 10% generally indicating
poor prognosis (Johannessen and Torp, 2006). The observed ac-
tivity-regulated increase in proliferation was restricted to the
active circuit; in the prefrontal cortex, a region infiltrated by gli-
oma cells but outside of the area stimulated by light, glioma
cell proliferation indices were equivalent in Thy1::ChR2;NSG
and WT;NSG mice (Figures S1D and S1E). While proliferation
increased within the active circuit, glioma cell death remainedconstant, with only rare tumor cells expressing cleaved cas-
pase-3 in either group (Figures S1F and S1G).
A simplified Galton-Watson mathematical model (Gerlee,
2013) of tumor cell growth incorporating the neuronal activity-
associated increase in proliferation index (b) and a fixed cell
death rate (d) would predict an exponential growth effect of
elevated neuronal activity within the active circuit (xt =
x0(1+(b-d))
t). Such a model utilizing the observed proliferation
indices predicts an activity-regulated 25% increase in tumor
cell number after seven cell divisions and 50% tumor increase
after 14 divisions. To test this prediction in vivo, we utilized a re-
petitive stimulation paradigm in whichmice were optogenetically
manipulated as above for 10min daily on 7 consecutive days and
were sacrificed 48 hr after the final session. Following repetitive
elevations in premotor circuit activity, tumor cell proliferation in-
dex was increased in xenografted Thy1::ChR2;NSG mice to a
similar degree as in the single optogenetic stimulation paradigm
(10.74% ± 0.61 versus 7.72% ± 0.88; n = 4 Thy1::ChR2;NSG
mice, n = 5 WT;NSG mice; p < 0.05, Figure 1F). As predicted,
periodically elevated neuronal activity for 1 week yielded a
42% increase in tumor cell burden within the active circuit
relative to identically manipulated WT controls (n = 4 Thy1::
ChR2;NSG, n = 5 WT;NSG mice; p < 0.01; Figures 1G and 1H).
These data reflect the influence of neuronal activity on tumor
burden during the exponential growth phase; over the course
of the disease, as disruption of healthy tissue progresses and
the microenvironment evolves, the effects of neuronal activity
on glioma growth could change.
Neuronal Activity Promotes Glioma Proliferation
through Secreted Factors
To determine whether neurons stimulate glioma proliferation via
secretion of an activity-regulated mitogen(s), we optogenetically
stimulated acute cortical slices from Thy1::ChR2 or identically
manipulated WT mice in situ and collected the conditioned me-
dium (CM), to which we exposed patient-derived HGG cultures
(Figure 2A). The slice stimulation paradigm mirrored the in vivo
paradigm, using 473 nm light at 20 Hz for cycles of 30 s on,
90 s off over a 30 min period. For this in situ optogenetic model,
expected neuronal firing in response to light was validated elec-
trophysiologically, confirming 20 Hz spike trains for 30 s periods
throughout the 30 min session (Figure 2B). Maintenance of slice
health throughout this paradigm was confirmed electrophysio-
logically and histologically (Figures S2A–S2D). Cortical slices
from WT mice were identically manipulated for comparison.
In parallel, CM was collected from blue light-unexposed
Thy1::ChR2 and WT cortical slices. Patient-derived HGG cul-
tures were then placed in CM from stimulated (light-exposed)
or unstimulated cortical slices (Figure 2A). The HGG cell prolifer-
ation index (fraction of total cells in S phase as detected by EdU
incorporation) was determined after 24 hr exposure to CM from
the acute cortical slice conditions described above. The CM
from optogenetically stimulated Thy1::ChR2 cortical slices
(active CM) increased the in vitro proliferation index of pHGG
(SU-pcGBM2) cells in comparison to CM from all control condi-
tions, including identically manipulated WT, unstimulated
Thy1::ChR2, or unstimulatedWT cortical slices, or in comparison
to blue light-exposed or non-exposed aCSF medium lackingCell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc. 805
Figure 2. Activity-Regulated Secreted Factors Promote Glioma Cell Proliferation
(A) Schematic depicts optogenetic stimulation of acute cortical slices and collection of conditioned medium (CM).
(B) Electrophysiological demonstration by patch-clamp recording (left; trace highlighted in red is magnified at right) of 20 Hz neuronal firing in response to 20 Hz
blue light pulses throughout the 30 s stimulation period in the Thy1::ChR2 cortical slice.
(C) Representative confocal micrographs show increased uptake of EdU (red) in cells (DAPI, blue) exposed to CM from stimulated Thy1::ChR2 slices (active CM)
versus those exposed to CM from blue light-exposed WT slices (WT CM).
(D) Proliferation index of SU-pcGBM2 cells exposed to optogenetically stimulated or unstimulated Thy1::ChR2 cortical slice CM, blue light-exposed WT cortical
slice CM (‘‘WT stim CM’’) or non-exposed WT cortical slice CM (‘‘WT unstim CM’’), or plain media (aCSF).
(E) Proliferation index of SU-pcGBM2 cells after exposure to CM generated from light-unexposed WT slice conditioning for 4 hr in the presence or absence of
1 mM tetrodotoxin (TTX).
(F–I) Active CM similarly increased the proliferation index of DIPG (F and G), adult GBM (H), and anaplastic oligodendroglioma (I) cultures.
(J–N) Active CM increased the viable cell number measured by CellTiter-Glo after 72 hr of incubation with active or light-exposed WT CM in pediatric and adult
GBM (J and M), DIPG (K and L), and anaplastic oligodendroglioma (N) cells.
All experiments analyzed by one-way ANOVA and performed with n = 3 biological replicates. Data shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001. Scale bars, 100 mm. See also Figure S2 and Table S1.slices (F = 15.49, p < 0.0001; Figures 2C and 2D). Active CM did
not alter glioma cell death, as assessed by Annexin V FACS anal-
ysis (Figure S2E). The secretion of activity-regulated mitogen(s)
was not frequency dependent, as CM from Thy1::ChR2 cortical
slices optogenetically stimulated at 5 Hz elicited the same prolif-
erative effect on pHGG cells (Figure S2F).
WT cortical slices do exhibit spontaneous neuronal activity;
thus, we expect activity-regulated secreted factors to be present
in WT CM, albeit to a lesser extent than in media conditioned by806 Cell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc.Thy1::ChR2 slices with optogenetically elevated neuronal activ-
ity. To further explore the possible effects of spontaneous activ-
ity, we allowed WT slices to condition the media without blue
light for 4 hr rather than 30 min in the presence or absence of
the specific voltage-gated sodium channel blocker tetrodotoxin
(TTX) to silence spontaneous action potentials. WT CM condi-
tioned for a longer duration elicited an increase in pHGG prolifer-
ation; this effect was blocked in CM from slices incubated with
TTX (proliferation index 0.32 ± 0.03 with 4 hr WT CM exposure
versus 0.25 with aCSF, aCSF + TTX, or WT CM + TTX expo-
sure; F = 8.45; p < 0.01; Figure 2E). Together, these data indicate
that spontaneous neuronal activity regulates secretion of a gli-
oma mitogen(s).
To determine whether this proliferative response to activity-
regulated secreted factor(s) was specific to the pHGG model
(SU-pcGBM2 cells) or more broadly applicable, we tested nine
additional patient-derived HGG cell cultures (Table S1). All four
tested cultures of diffuse intrinsic pontine glioma (DIPG), the
most common form of pediatric HGG, demonstrated a similarly
robust proliferative response to active CM exposure (Figures
2F, 2G, S2G, and S2H).We next tested four patient-derived adult
GBM cultures and found a similar increase in cell proliferation
after exposure to active CM (Figures 2H, S2I, and S2J) in all
but one, which was a young adult epithelioid BRAFV600E mutant
GBM (SU-GBM047; Figure S2K). As the mitogenic effect ap-
pears largely generalizable across distinct HGG classes, we
also tested a patient-derived culture of adult anaplastic oligo-
dendroglioma and similarly observed increased cell proliferation
in response to activity-regulated secreted factors (Figure 2I).
Consistent with spontaneous neuronal activity of WT slices,
some cultures exhibit a small but significant increase in prolifer-
ation in response to WT CM (e.g., SU-DIPGVI, proliferation index
0.21 ± 0.01 in aCSF versus 0.31 ± 0.02 in WT CM versus 0.46 ±
0.002 in active CM; Figures S2G and S2J).
To ascertain whether the observed effect indicated an in-
crease in overall glioma growth, we used the quantitative viable
cell assay CellTiter-Glo following 72 hr exposure to cortical
slice CM and found an increase in viable HGG cell number
when cultures were exposed to active CM (Figures 2J–2N and
S2L–S2N).
Activity-Regulated Glioma Mitogen(s) Are Secreted
Proteins
A series of biochemical analyses was employed to ascertain
the nature of the activity-regulated mitogen(s). To determine
whether the mitogen(s) are small molecules or macromole-
cules, active or control CM was collected as above and frac-
tionated by molecular size. The >10 kDa macromolecular
fraction of active CM, but not the <10 kDa fraction, increased
the in vitro glioma proliferation index (Figure 3A). Subsequent
fractionation indicated that the mitogen(s) were present in
the <100 kDa fraction (Figure 3B). To determine the biochem-
ical nature of the mitogen(s), active CM was heated to
>100C to denature proteins, resulting in loss of its mitogenic
effect (Figure 3C). In contrast, treatment of active CM with
RNase and DNase had no effect on its proliferation-inducing
capacity (Figure 3D). Taken together, these data indicate that
the neuronal activity-regulated secreted mitogen(s) is a protein
between 10–100 kDa.
With respect to small molecules, high levels of glutamate
release into CM would not be expected in a healthy brain slice,
as perisynaptic astrocytes take up released glutamate from the
synaptic cleft (Rothstein et al., 1996). Indeed, low levels of gluta-
mate were present in active CM (Figure S3A). Thus, this in situ
experimental paradigm does not address the potential role of
glutamate in neuronal activity-regulated glioma cell proliferation
in vivo.Cortical Projection Neuronal Activity-Regulated
Secretome
To identify the secreted protein(s) that increase glioma cell prolif-
eration in an activity-dependent manner, we employed mass
spectrometric analyses of the cortical sliceCM.Of note, neuronal
activity may regulate secretion of proteins from neurons them-
selves or from other cell types in response to active neurons.
Active CM and light-exposed WT CM were analyzed and com-
pared using 2D gel electrophoresis to separate the secreted pro-
teins by size and charge; differentially secreted protein spots
were then identified by mass spectrometry. The 2D gel analyses
were performed in duplicate using independent samples (Fig-
ure 3E). Quantitative mass spectrometric techniques of spectral
counting and tandemmass tags (TMT)were thenusedwith a third
set of independent samples to confirm the 2D gel results and to
more precisely define the absolute and relative quantities of
each protein in the CM samples. The intersection of these
analyses most consistently and robustly identified neuroligin-3
(Nlgn3) as the leading candidate mitogen (Figure 3F), present in
active CM at a concentration of 20–40 nM and upregulated by
2.6-fold compared to light-exposed WT CM. Additional candi-
dates identified are listed in Figure 3G.
The neuroligins are a family of synaptic proteins with a large
N-terminal ectodomain, single pass transmembrane domain,
and smaller C-terminal cytoplasmic domain (Su¨dhof, 2008).
Neuroligin-1 (Nlgn1), acting primarily at excitatory synapses
similarly to Nlgn3, is secreted in an activity-regulated fashion
by enzymatic cleavage of the N-terminal ectodomain (Peixoto
et al., 2012; Suzuki et al., 2012). The 2D gel and quantitative
mass spectrometric analyses across all three independent sam-
ples demonstrated excellent coverage of the Nlgn3 ectodomain
amino acid sequence (protein prophet score = 1; Table S2), iden-
tifying the protein with high confidence (Figure 3H). However, the
C-terminal transmembrane and cytoplasmic domain of the pro-
tein was not detected in Nlgn3 isolated from the active CM
(Figure 3H).
Secreted Neuroligin-3 Promotes Glioma Cell
Proliferation
The sufficiency of NLGN3 to promote HGG cell proliferation was
then tested in vitro. We obtained recombinant full-length human
NLGN3 and confirmed its identity and purity by mass spectrom-
etry (Figure S3B). In contrast to the Nlgn3 present in the CM,
mass spectrometric analysis of recombinant NLGN3 did identify
peptide sequences within the C-terminal tail. 24 hr exposure of
pHGG cells to recombinant NLGN3 at various concentrations
in vitro promoted a significant increase in proliferation index (Fig-
ure 4A), with no change in cell death as measured by Annexin V
FACS analysis (Figure 4B). NLGN3 at the concentration present
in the active CM (20–40 nM) elicits an increase in proliferation
commensurate with the effect of active CM (Figures 4A and
2D). NLGN3 promoted proliferation of each additional patient-
derived cell culture tested, including DIPG, adult GBM, and
anaplastic oligodendroglioma, with the exception of the epithe-
lioid GBM culture (Figures 4C and S4A).
Additional candidates identified in the proteomic analyses
above were also screened in pHGG cells in vitro. Of these,
brain-derived neurotrophic factor (BDNF) and the known gliomaCell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc. 807
Figure 3. Cortical Neuronal Activity-Regulated Glioma Mitogen(s) Are Protein(s)
(A and B) Fractionation of CM by molecular size reveals that the activity-regulated mitogenic factors are >10 kDa (A) and <100 kDa (B).
(C) Heating active CM to 100C inactivates the mitogen(s).
(D) RNA and DNA digestion of active CM does not change its mitogenic effect. All experiments analyzed by one-way ANOVA and performed with n = 3 biological
replicates. Data shown as mean ± SEM. **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s. indicates p > 0.05.
(E) Representative two-dimensional gel electrophoresis separating proteins in light-exposedWT CM (green) and active CM (red) by size (vertical axis) and charge
(horizontal axis); merged images, right-most panel.
(F) Volcano plot of spectral counting data shows the ratio of peptides in a given protein found in active CM versus CM from unstimulated Thy1::ChR2 slices.
Neuroligin-3 (Nlgn3) is highlighted and circled in red.
(G) List of candidate proteins of interest identified from proteomic analyses.
(H) Nlgn3 peptide sequence. Peptides in red were identified by mass spectrometry of the Nlgn3 isolated from active CM. Despite excellent coverage across the
N-terminal ectodomain of the protein, no part of the C-terminal endodomain (transmembrane and intracellular domains, shaded gray) was identified in the
isolated soluble Nlgn3.
See also Figure S3 and Table S2.mitogen 78 kDa glucose-regulated protein (GRP78; Lee et al.,
2008) promoted pHGG proliferation but less potently than
NLGN3 (Figures S4B–S4D). Additional candidates tested did
not affect proliferation, even at high concentrations (Figure S4B).
Thus, NLGN3 emerged as an unexpected cortical neuronal ac-
tivity-regulated glioma mitogen, together with known mitogens
BDNF and GRP78.
To test the necessity of Nlgn3 for the proliferation-promoting
effect of active CM, we utilized the specific and avid binding of
neurexin-1b (NRXN1b) to NLGN3 (Ichtchenko et al., 1996) to
deplete Nlgn3 from the cortical slice CM. Confirming that
NRXN1b in this setting does deplete the available Nlgn3, addition
of NRXN1b completely abrogated themitogenic effect of recom-
binant NLGN3 exposure (proliferation index 0.40 ± 0.01 in pHGG808 Cell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc.cells exposed to 50 nM NLGN3 versus 0.28 ± 0.01 in cells
exposed to 50 nM NLGN3 + 500 nM NRXN1b; p < 0.001; Fig-
ure 4D). Addition of NRXN1b alone to aCSF or to WT CM had
no effect on proliferation index (Figure 4D). However, addition
of NRXN1b significantly decreased the mitogenic effect of active
slice CM on pHGG cells (proliferation index 0.40 ± 0.01 in cells
exposed to active CM versus 0.34 ± 0.01 with exposure to active
CM + NRXN1b; p < 0.05; Figure 4D), indicating that secreted
NLGN3 is necessary for the full mitogenic effect of cortical
neuronal activity on glioma cells. The incomplete abrogation of
the mitogenic effect of the CM with addition of NRXN1b is
consistent with additional activity-regulated glioma mitogens
GRP78 and BDNF present in the CM (Figures S4B–S4D). Indeed,
pharmacological inhibition of the BDNF receptor TRKB in
Figure 4. Secreted Neuroligin-3 Mediates Neuronal Activity-Regulated Glioma Proliferation
(A) Seven-point dose curve plots SU-pcGBM2 proliferation index asmeasured by EdU+/DAPI+ staining 24 hr after exposure to recombinant NLGN3 at a 0–100 nM
concentration range. Shaded region indicates concentration present in active CM.
(B) After 24 hr exposure to PBS or NLGN3 (50 nM), SU-pcGBM2 cells were stained with DAPI (x axis) and Annexin V-FITC (y axis) to detect cell death by FACS
analysis, performed in biological duplicate. Live Annexin V/DAPI cells shown in lower-left quadrant of contour plots; pre-apoptotic Annexin V+/DAPI cells, left
upper quadrant; dead Annexin V+/DAPI+ cells, right upper quadrant. No increase in cell death was seen with NLGN3 exposure.
(C) Proliferation indices of various patient-derived HGG cell lines exposed to 50 nM NLGN3 for 24 hr (unpaired two-tailed Student’s t tests).
(D) Neurexin-1b (NRXN, 500 nM), which binds NLGN3 with high affinity, effectively blocks the mitogenic effect of recombinant NLGN3 (50 nM) and abrogates the
mitogenic effect of active CM (unpaired two-tailed Student’s t tests). Exposure to NRXN alone or added to light-exposed WT CM (‘‘WT Stim CM’’) does not affect
pHGG cell proliferation (one-way ANOVA).
For all experiments, n = 3 biological replicates unless otherwise noted. Data shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. n.s. indicates p > 0.05. See
also Figure S4.combination with NRXN1b completely abrogated the prolifera-
tive effect of active CM (Figure S4E).
Downstream Mechanisms of Neuronal
Activity-Regulated Glioma Proliferation
To begin to understand the intracellular signaling mechanisms
by which neuronal activity promotes HGG cell proliferation, we
performed RNA sequencing to define the transcriptome of
pHGG cells exposed to active CM versus light-exposed WT
CM. Pathway analysis of differentially regulated genes revealed
upregulation of the immediate early gene and proto-oncogene
FOS, whose expression can be downstream of pathways that
include PI3K-mTOR signaling or MAPK signaling (Greenberg
and Ziff, 1984; Gonzales and Bowden, 2002; Chen and Davis,
2003), suggesting potential involvement of either pathway
(Table S3). Exposure to NLGN3 similarly resulted in upregulation
of FOS expression, determined by qPCR (Figure 5A). However,
western blot analysis did not reveal upregulation of phospho-
ERK1/2T202/Y204, an indicator of MAPK pathway activation,
following NLGN3 exposure (Figures S5A and S5B). We thusexamined PI3K pathway recruitment by exposure to NLGN3
using western blot analysis of phospho-AKTS473; pHGG cells
exposed to NLGN3 exhibited increased phospho-AKTS473 levels
relative to total AKT in a dose-dependent manner (F = 17.99,
p < 0.001; Figure 5B-C). PI3K canonically regulates mammalian
target of rapamycin (mTOR), and thus we examined the effect
of NLGN3 exposure on mTOR activity using western blot
analysis of phospho-4E-BP1T37/46, revealing an increase in
phospho-4E-BP1T37/46 relative to total 4E-BP1 following
NLGN3 exposure (Figures 5D and 5E). Blockade of PI3K or
mTOR pharmacologically or via shRNA-mediated knockdown
prevented the NLGN3-mediated mitogenic effect (Figures 5F–
5H and S5C–S5E). Neuronal activity-regulated secretion of
NLGN3 thus recruits the PI3K-mTOR pathway to promote gli-
oma cell proliferation.
Surprisingly, we also found upregulated expression of the
neuroligin-3 gene (NLGN3) in pHGG cells exposed to active
CM (Table S3), suggesting a positive feedforward effect on gli-
oma cell NLGN3 expression. To determine whether soluble
NLGN3 exposure induces its own expression, we performedCell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc. 809
Figure 5. Secreted Neuroligin-3 Recruits the PI3K Pathway and Promotes Feedforward Expression of NLGN3
(A) FOS mRNA expression increases after 1 hr exposure to 50 nM NLGN3 compared to vehicle (p < 0.01 by unpaired two-tailed Student’s t test).
(B) NLGN3 increases PI3K pathway signaling. Representative western blot shows increased phosphorylation of AKT (pAKTS473, top; total AKT, bottom) in
response to NLGN3 concentrations ranging from 0 to 50 nM.
(C) Quantification of the pAKTS473/AKT ratio fold change (normalized to aCSF) observed in (B).
(D) Representative western blot demonstrates increased phosphorylation of 4E-BP1, a downstream reporter of mTOR, after 50 nM NLGN3 exposure. (Top)
4E-BP1T37/46; (bottom) total 4E-BP1.
(E) Quantification of p4E-BP1T37/46/4E-BP1 ratio fold change after NLGN3 exposure normalized to aCSF control (unpaired two-tailed Student’s t test).
(F) 50 nM NLGN3-induced increase in SU-pcGBM2 proliferation index (EdU assay) is blocked by inhibition of PI3K by BKM120 (100 nM).
(G) Similar to (F), inhibition of mTOR by RAD001 (100 nM) blocks 50 nM NLGN3-induced proliferation in SU-pcGBM2 cells.
(H) Genetic knockdown using specific shRNA against either PI3K ormTOR blocks effect of 50 nM NLGN3 on proliferation index (EdU assay in SU-pcGBM2). *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way ANOVAwith Tukey’s post hoc tests to further examine pairwise comparisons unless otherwise indicated.
All experiments performed in n = 3 biological replicates. Data shown as mean ± SEM. See also Figure S5 and Table S3.qPCR in cells exposed to recombinant NLGN3 and found that
this elicits increased glioma cell NLGN3 gene expression, tested
in both pediatric cortical HGG (F = 9.70, p < 0.01; Figure 6A) and
DIPG cells (F = 13.56, p < 0.01; Figure 6B). The role of PI3K-
mTOR pathway activity in this positive feedforward effect was
investigated using treatment with the PI3K inhibitor BKM120 or
shRNA-mediated PI3K knockdown (Figures 6A–6D), both of
which blocked the soluble NLGN3-induced increase in NLGN3
gene expression (Figures 6A–6D and S6). Similarly, the mTOR
inhibitor RAD001 or shRNA-mediated mTOR knockdown pre-
vented the feedforward effect of NLGN3 onNLGN3 gene expres-
sion (Figures 6C and 6E–6G). Soluble NLGN3 thus promotes
glioma cell feedforward expression of NLGN3 via the PI3K-
mTOR pathway. To determine whether other ligands known to
stimulate the PI3K pathway in glioma (Fan et al., 2009) similarly
affect NLGN3 expression, we tested the effect of epidermal
growth factor (EGF) exposure on glioma cell NLGN3 expression
and found no effect (p = 0.781; Figure 6H), suggesting that
NLGN3 expression is specific to the context of NLGN3 exposure.
Protein expression of NLGN3 following glioma cell NLGN3 expo-
sure was confirmed using western blot analysis; in contrast, gli-
oma cell NLGN3 protein expression was not found at baseline
culture conditions (Figure 6I). NLGN3 thus results in feedforward810 Cell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc.expression at the transcriptional and translational levels.
Together, these findings indicate that NLGN3 expression is an
indicator of neuronal activity-dependent NLGN3 signaling to gli-
oma cells (Figure 6J).
Neuroligin-3 Gene Expression Is Associated with
Decreased Survival in Human High-Grade Glioma
Having demonstrated that NLGN3 exposure increases tumor cell
NLGN3 expression, we next asked whether theNLGN3 gene ex-
hibited aberrations in glioma. Analysis of data from The Cancer
Genome Atlas (TCGA) showed that somatic mutations in
NLGN3 are infrequent in pediatric (pilocytic astrocytoma/medul-
loblastoma, 0.4%) and adult brain tumors (low-grade gliomas,
1.1%; high-grade gliomas, 0.4%; Table S4). Interestingly, an
extended analysis of NLGN3mutations and copy-number aber-
rations across multiple cancer types in the International Cancer
Genome Consortium (ICGC) and the cBioPortal for Cancer
Genomics databases revealed more frequent mutations and
amplifications in other tumors, with particular predominance in
thyroid, pancreatic, prostate, and gastric cancers (Figure S7C
and Table S4).
To validate the clinical significance of NLGN3 in human glioma
pathophysiology, we next examined the relationship between
Figure 6. Secreted Neuroligin-3 Promotes Feedforward Expression of NLGN3 through Recruitment of the PI3K-mTOR Pathway
(A) NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.
(B) As in (A), SU-DIPGXIII NLGN3 mRNA expression after exposure to NLGN3 and BKM120 alone or in combination.
(C–E)NLGN3mRNA expression in SU-pcGBM2 cells after shRNA-mediated knockdown of eitherPI3K ormTOR. Only cells exposed to scrambled shRNA control
exhibit increased NLGN3 expression after NLGN3 exposure (unpaired two-tailed Student’s t test.)
(F) NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM RAD001, or 50 nM NLGN3 + 100 nM RAD001.
(G) As in (F), SU-DIPGXIII NLGN3 mRNA expression after exposure to NLGN3 and RAD001 alone or in combination.
(H) NLGN3 mRNA expression in SU-pcGBM2 cells does not change after 12 hr exposure to 50 nM EGF versus vehicle (unpaired two-tailed Student’s t test). All
qPCR data (A–H) are normalized to vehicle-treated samples and represent fold change of the delta CT in reference to b-actin.
(I) Western blot analysis illustrating NLGN3 protein expression. Lanes 1 and 2 = 10 nM and 25 nM recombinant FLAG-tagged NLGN3, respectively. Lanes 3 and
4 = lysate from SU-pcGBM2 cells exposed to aCSF or 50 nM recombinant FLAG-tagged NLGN3, respectively. Top panel probed with anti-NLGN3; bottom panel
probed with anti-FLAG.
(J) Schematic illustrating the model of neuronal activity-regulated NLGN3 secretion from a post-synaptic cell, subsequent recruitment of glioma cell PI3K-mTOR
pathway, expression of FOS and NLGN3, and proliferation.
n = 3 biological replicates unless otherwise stated. Data shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA unless otherwise stated.
n.s. indicates p > 0.05. See also Figure S6 and Table S3.NLGN3 gene expression and patient survival in 429 cases of
adult GBM in TCGA. NLGN3 mRNA expression level was found
to be inversely correlated with patient overall survival (Figure 7).
A two-class model in which patients were stratified according to
median NLGN3 expression showed an association between
higher NLGN3 expression and shorter survival (p < 0.05 by the
log-rank test; Figure 7A). In patients whose tumors exhibitedbelow-median NLGN3 expression, estimated mean survival
was 20.8 months (95% CI, 17.1–24.4); in comparison, mean sur-
vival of patients with above-median NLGN3 expression was
15.2 months (95% CI, 13.1–17.2). On Cox regression analysis,
the hazard ratio for death with high versus low NLGN3 expres-
sion was 1.31 (95% CI, 1.05–1.63). NLGN3 expression was
also significantly inversely associated with patient survival in aCell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc. 811
Figure 7. Neuroligin-3 Expression Inversely
Correlates with Survival in Human Glio-
blastoma
(A) A two-class model stratified by median
NLGN3 expression in 429 GBM cases with
molecular subtype data from the TCGA (http://
cancergenome.nih.gov). Mean overall survival
decreases by5.6 months in patients with tumors
exhibiting above-median NLGN3 expression; p <
0.05 by the log-rank test.
(B) GBM subtype-specific NLGN3 expression.
Box plots show the smallest and largest obser-
vations (top and bottom whiskers, respectively),
the interquartile (IQ) range (box), and the median
(black line). Data points more than 1.5 times the IQ
range lower than the first quartile or 1.5 times the
IQ range higher than the third quartile were
considered outliers (shown as circles outside the
box and whisker plot). Corresponding table of
Kruskal-Wallis one-way ANOVAs with p values
indicates pairwise comparisons of NLGN3
expression in the four subtypes and significance of
differential NLGN3 expressions. See also Fig-
ure S7, Table S4.continuous Cox proportional-hazards regression analysis, such
that higher expression represented an unfavorable prognosis
(hazard ratio for death with high versus low NLGN3 expression,
1.15; 95% CI, 1.01–1.30; p < 0.05).
To examine the specificity of these findings, we explored the
relationship of neuroligin-2 (NLGN2) to survival in human GBM.
Recombinant NLGN2 does not promote pHGG proliferation
in vitro (Figure S7D). Likewise, there is no significant association
between NLGN2 expression and patient survival in adult GBM,
assessed as above in a continuous Cox model (hazard ratio for
death with high versus low NLGN2 expression, 0.95; 95% CI,
0.78–1.16; p = 0.634) and in a two-class model stratified by me-
dian expression (p = 0.795 by the log-rank test; Figure S7E).
Interestingly, upon examination of NLGN3 expression by mo-
lecular GBM subtype as defined by TCGA (Verhaak et al., 2010),
NLGN3 expression was significantly lower in the mesenchymal
subtype compared to classical, neural, and proneural subtypes
(asymptotic significance of p < 0.001 by independent-samples
Kruskal-Wallis test; Figure 7B). Notably, NLGN3 expression re-
mained significantly associated with patient survival in a multi-
variate Cox model that incorporates molecular subtype (hazard
ratio for death with high versus low NLGN3 expression, 1.15;
95% CI, 1.01–1.30; p < 0.05).812 Cell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc.DISCUSSION
Neurons in the Glioma
Microenvironment
The results presented here demonstrate
that excitatory neuronal activity can
influence brain cancer growth. This repre-
sents a striking example of the core phys-
iological function of an organ promoting
the growth of a cancer arising within it.
An important mechanism mediating thiskey microenvironmental interaction is activity-regulated secre-
tion of NLGN3. The importance of NLGN3 in HGG pathophysi-
ology is underscored by the finding that NLGN3 expression
strongly predicts survival in human HGG. Taken together, these
data elucidate a fundamental dimension of the HGG microenvi-
ronment and identify a robust and targetable mechanism driving
HGG proliferation.
The role that neurons may play in brain cancer is underscored
by perineuronal satellitosis, the histopathological hallmark of
multiple forms of glioma characterized by tumor cell clustering
around neuronal somata (Scherer 1938). A wealth of elegant
data illustrates that neurotransmitters and neuropeptides can
affect glioma cell behavior (Cuddapah et al., 2014; Labrakakis
et al., 1998; Seifert and Sontheimer, 2014; Synowitz et al.,
2001); for example, glutamate secreted from glioma cells influ-
ences their own proliferation and invasion through autocrine/
paracrine signaling and subsequently increases the excitability
of affected cortical networks (Buckingham et al., 2011; Campbell
et al., 2012; Ishiuchi et al., 2002, 2007). However, a direct influ-
ence exerted by active parenchymal neurons upon the glioma
environment has not been well appreciated. The critical role of
neural elements in the cancer microenvironment has recently
been elucidated for prostate (Magnon et al., 2013), pancreatic
(Stopczynski et al., 2014) and gastric (Zhao et al., 2014) cancers,
in which peripheral innervation was found to potently promote
cancer progression. Our results suggest that active neurons
play an important role in the microenvironment of brain tumors
through malignant hijacking of mechanisms central to brain
plasticity.
Normal and Malignant Neuron-Glial Interactions
A surprisingly broad range of molecularly and clinically distinct
classes of HGG exhibited neuronal activity-regulated prolifera-
tion, and this response to neuronal activity mirrors that of puta-
tive HGG cells of origin. While the cellular origins of HGG may
vary among subtypes of the disease, mounting evidence sug-
gests that not only oligodendrogliomas (Persson et al., 2010;
Sugiarto et al., 2011), but also many high-grade astrogliomas,
arise from precursor cells in the oligodendroglial lineage,
including NPCs/early OPCs (Monje et al., 2011) and OPCs (Liu
et al., 2011; Galvao et al., 2014; Glasgow et al., 2014). OPCs,
the most mitotically active cells in the postnatal brain (Geha
et al., 2010), may be particularly susceptible to malignant trans-
formation due to Olig2-mediated suppression of p53 function
(Mehta et al., 2011). Overexpression of a single transcription fac-
tor can determine the oligodendroglial or astrocytic phenotype of
oligodendroglial lineage cell-derived tumors (Glasgow et al.,
2014). A salient example of this point is the tumor from which
the adult GBM culture SU-GBM052 used in this study was
derived, a grade IV astrocytoma apparently arising from a trans-
formed grade II oligodendroglioma. The ‘‘proneural,’’ and to a
lesser extent the ‘‘neural’’ and ‘‘classical,’’ molecular subtypes
of adult GBM, are defined by expression of oligodendroglial line-
age-associated genes (Verhaak et al., 2010). Intriguingly, our
data demonstrate that NLGN3 is expressed abundantly in these
three subtypes of GBM compared to ‘‘mesenchymal’’ GBM,
supporting the concept of a lineage-specific molecular rele-
vance of NLGN3 to gliomagenesis. Normal NPCs and OPCs
respond briskly to neuronal activity, and in the healthy juvenile
and adult brain this response results in the activity-regulated
generation of mature oligodendrocytes and remodeling of
myelin, improving the function of that active circuit (Gibson
et al., 2014). The findings presented here suggest that the malig-
nant counterparts of these activity-responsive neural precursor
cells may exploit mechanisms of myelin development and plas-
ticity to promote growth.
Neuroligin-3 in Health and Disease
The finding that NLGN3 is a glioma mitogen opens numerous
doors to a deeper mechanistic understanding of its role in health
and disease. The neuroligins are post-synaptic adhesion mole-
cules that are important in synaptic function and plasticity (Su¨d-
hof, 2008; Varoqueaux et al., 2006). Nlgn1 andNlgn3 are found in
excitatory synapses, while Nlgn2 participates in inhibitory syn-
apses (Gibson et al., 2009; Su¨dhof, 2008). The canonical binding
partners of the neuroligins are presynaptic b-neurexins (Ichtch-
enko et al., 1996; Su¨dhof, 2008). While wild-type neuroligins
play a central role in normal synaptic function, NLGN3mutations
are implicated in altered synaptic function in autism (Jamain
et al., 2003; Rothwell et al., 2014; Tabuchi et al., 2007). Our
data show that somatic mutations and amplifications inNLGN3 are also found at varying frequency in different types of
human malignancies, supporting a possibly broader role of
NLGN3 in cancer. Such mutations are less frequent in gliomas,
implying that non-genetic mechanisms of NLGN3 deregulation
may predominate in neoplasms of organs that normally express
NLGN3. Suchmechanismsmay include, as we show here, activ-
ity-regulated secretion coupled with a positive feedforward
effect on expression. Interestingly, NLGN3mutations and ampli-
fications are prominent in pancreatic, prostate, and gastric can-
cers, for which a cancer growth-promoting role of innervation
has been demonstrated (Stopczynski et al., 2014; Magnon
et al., 2013; Zhao et al., 2014).
Neuroligin Secretion
Nlgn1 and Nlgn2 are known to undergo activity-dependent
cleavage at the C-terminal transmembrane and cytoplasmic
domain with resultant secretion of the N-terminal ectodomain
(Peixoto et al., 2012; Suzuki et al., 2012). The data presented
here illustrate activity-regulated secretion of Nlgn3 in the context
of cortical projection neuronal activity. The mechanism of Nlgn3
secretion remains to be seen, but the apparent absence of the
C-terminal transmembrane and cytoplasmic domain in the
Nlgn3 protein identified in the active slice CM suggests similar-
ities with mechanisms of Nlgn1 and Nlgn2 secretion. Given the
enormous complexity of neurexin splice variants (> 1,000; Ullrich
et al., 1995) and possible alternative binding partners (Samarelli
et al., 2014), the identity of the binding partner for NLGN3 in gli-
oma cells remains an open question for further exploration.
While the present study provides evidence that active neurons
promote HGG proliferation, this intercellular interaction may be
indirect. Neuronal activity influences multiple cell types within
an active neural circuit, and numerous activity-responsive cell
types could play a role in promoting glioma growth. It is possible
that NLGN3 is secreted directly from active neurons or from
OPCs, which act as post-synaptic cells in axoglial synapses
(Bergles et al., 2010; Bergles et al., 2000) and express the highest
level of Nlgn3 mRNA of any neural cell type (Zhang et al., 2014).
Neuroligin-3, PI3K Pathway, and Feedforward
Expression
How NLGN3 recruits the glioma cell PI3K pathway is not yet
clear, but links between neuroligin binding and receptor tyrosine
kinase (RTK) activation, frequently upstream of PI3K, have been
described in other contexts. Nlgn1 binding to Nrxn1b in presyn-
aptic neurons promotes neurite outgrowth in a manner that de-
pends upon Nrxn1b-mediated activation of the RTK fibroblast
growth factor receptor-1 (Fgfr1; Gjørlund et al., 2012). A similar
NRXN-RTK interaction may mediate NLGN3 stimulation of
PI3K activity in HGG if a NRXN family member is indeed the bind-
ing partner of NLGN3 in glioma cells.
PI3K-mediated feedforward regulation of NLGN3 gene and
protein expression was unexpected.NLGN3 is not part of the ca-
nonical PI3K gene expression signature (Creighton et al., 2010),
and, as demonstrated above, other growth factors known to
stimulate PI3K such as EGF do not elicit changes in NLGN3
gene expression in glioma cells, indicating that NLGN3 is not a
general marker of PI3K activity but is rather specific to this
context. PI3K has been shown to regulate Nlgn1 and Nlgn2Cell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc. 813
translation (Gkogkas et al., 2013), suggesting another link be-
tween PI3K pathway activity and regulation of NLGN3 expres-
sion. Future work will elucidate the manner in which NLGN3
recruits PI3K and subsequently promotes feedforward glioma
NLGN3 expression.
Additional Mechanisms of Neuronal Activity-Regulated
Glioma Proliferation
It is also important to note that NLGN3 is almost certainly not the
only important mechanism promoting activity-regulated glioma
growth. Indeed, GRP78 and BDNFwere also identified as glioma
mitogens, and accordingly, Nlgn3 depletion resulted in a signif-
icant but incomplete abrogation of the mitogenic capacity of
the CM, indicating partial contributions from other mitogens
such as these. Recent single-cell analyses have elucidated intra-
tumoral cellular heterogeneity in HGG (Patel et al., 2014), and it is
not yet clear if these different activity-regulated mitogens act on
the same or different cellular subpopulations. The candidate ac-
tivity-dependent mitogens were recognized here via differential
regulation and secretion that enabled their identification in the
CM following a burst of cortical neuronal activity. Beyond these
candidates, additional possible mitogens could be secreted in a
more local manner or on a different timescale that precludes their
identification within this experimental paradigm. Cell-contact-
mediated mechanisms of activity-regulated glioma growth
were also not evaluated in our in situ system. One mechanism
that we do not evaluate explicitly is activity-regulated glutamate
release. Certainly, glutamate released by glioma cells (Bucking-
ham et al., 2011; Campbell et al., 2012; Ishiuchi et al., 2002,
2007) is well-demonstrated to promote glioma growth, and local
neuronal glutamate release could function similarly, possibly
contributing to the mitogenic effect of active neurons witnessed
in vivo.
Conclusions
NLGN3 was identified as an unexpected mitogen promoting
HGG growth. It is yet unclear whether NLGN3 similarly mediates
healthy myelin plasticity, which future work should address. If
that proves to be the case, this important synaptic protein could
represent a mechanism of coupling synaptic plasticity and
myelin plasticity. Regardless, neuron-glioma cell interactions,
including NLGN3 secretion and subsequent signaling to the
oncogenic PI3K-mTOR pathway in glioma cells, represent ther-
apeutic targets for this group of devastating brain tumors.
EXPERIMENTAL PROCEDURES
See the Extended Experimental Procedures for detailed experimental
procedures.
Isolation and Culture of the Primary Human Tumor Cells
Tumor tissue was dissociated and cultured as described in the Extended
Experimental Procedures.
Orthotopic Xenografting
600,000 SU-pcGBM2 cells were stereotactically implanted into theM2 premo-
tor cortex of Thy1::ChR2;NSG or WT;NSG littermate mice at P35. Cells were
allowed to engraft for at least 2 months prior to placement of an optical-neural
interface for optogenetic stimulation.814 Cell 161, 803–816, May 7, 2015 ª2015 Elsevier Inc.In Vivo Optogenetic Stimulation
At least 7 days prior to stimulation, the optical-neural interface was placed just
below the pial surface of the cortex ipsilateral to xenografts. For the single
stimulation paradigm, animals were stimulated with cycles of 473 nm light
pulses at 20 Hz for 30 s, followed by 90 s of recovery over a 30 min period
and sacrificed 24 hr after stimulation. For the repetitive stimulation paradigm,
animals were stimulated as above for 10 min periods on 7 consecutive days
and were sacrificed 48 hr after the final session.
Generation of Conditioned Media
In short, Thy1::ChR2 or WT mouse brains were cut in 350 mm sections on a
vibratome, allowed to recover, and stimulated at 20 Hz using a blue-light
LED transmitted through the microscope objective. Surrounding medium
was then collected for immediate use or frozen at 80C for future
experiments.
Determination of Cell Proliferation In Vitro
To assess the number of cells actively entering S phase in response to various
conditions (see Extended Experimental Procedures), patient-derived glioma
cell cultures were exposed to cortical slice CM or various recombinant pro-
teins along with 10 mM EdU and were fixed after 24 hr. EdU incorporation
was determined using Click-iT EdU visualization (Invitrogen).
Proteomic Analysis
Determination of proteins found within the active CM was done using 2D-gel
electrophoresis accompanied by LC MS/MS.
Western Blot Analysis
Protein levels were determined using western blot analyses. Briefly, after
various treatments, 400,000 SU-pcGBM2 cells were lysed and loaded onto
SDS-PAGE gels. Proteins were separated with gel electrophoresis and trans-
ferred to a PVDF membrane. Proteins were then probed with various anti-
bodies as described in Extended Experimental Procedures.
qPCR
After various cell treatments (described in Extended Experimental Proce-
dures), RNA was extracted from 500,000 SU-pcGBM2 or SU-DIPGXIII cells
using TRIzol reagent. cDNA was generated using RT-PCR, and gene expres-
sion changes were further probed using quantitative PCR.
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The accession number for RNA-seq data deposited in the GEO database is
GEO: GSE62563.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, one movie, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2015.04.012.
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